Skip to main content
Erschienen in: Osteoporosis International 5/2019

15.02.2019 | Case Report

Multiple vertebral fractures as the first manifestation of systemic mastocytosis

verfasst von: Á. Acosta-Mérida, S. Ojeda-Bruno

Erschienen in: Osteoporosis International | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Systemic mastocytosis is a clonal disease of the mast cell progenitors of the bone marrow. The clinical picture varies from asymptomatic (indolent) to highly aggressive (mast cell leukemia). Up to one-third of patients with SM have osteoporosis and fractures. The following is an analysis of the case of a young patient with multiple fractures as the first manifestation of SM.
Literatur
1.
Zurück zum Zitat Horny HP, Sotlar K, Valent P (2007) Mastocytosis: state of the art. Pathobiology 74:121–132CrossRefPubMed Horny HP, Sotlar K, Valent P (2007) Mastocytosis: state of the art. Pathobiology 74:121–132CrossRefPubMed
2.
Zurück zum Zitat Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NAT, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Investig 37:435–453CrossRef Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NAT, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Investig 37:435–453CrossRef
3.
Zurück zum Zitat Gülen T, Hägglun H, Dahlen B, Nilsson G (2015) Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease (review). J Intern Med 279(3):211–228 Gülen T, Hägglun H, Dahlen B, Nilsson G (2015) Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease (review). J Intern Med 279(3):211–228
4.
Zurück zum Zitat Rossini M, Zanotti R, Viapiana O, Tripi G, Orsolini G, Idolazzi L, Bonadonna P, Schena D, Escribano L, Adami S, Gatti D (2014) Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin N Am 34(2):383–396CrossRef Rossini M, Zanotti R, Viapiana O, Tripi G, Orsolini G, Idolazzi L, Bonadonna P, Schena D, Escribano L, Adami S, Gatti D (2014) Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin N Am 34(2):383–396CrossRef
5.
Zurück zum Zitat Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO study group. Osteoporos Int 4:368–381CrossRefPubMed Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO study group. Osteoporos Int 4:368–381CrossRefPubMed
6.
Zurück zum Zitat Degboé Y, Eischen M, Nigon D, Apoil PA, Mailhol C, Tournier E, Laurent C, Hanssens K, Hermine O, Paul C, Laroche M, Bulai-Livideanu C (2017) Prevalence and risk factors for fragility fracture in systemic mastocytosis. Bone 105:219–225CrossRefPubMed Degboé Y, Eischen M, Nigon D, Apoil PA, Mailhol C, Tournier E, Laurent C, Hanssens K, Hermine O, Paul C, Laroche M, Bulai-Livideanu C (2017) Prevalence and risk factors for fragility fracture in systemic mastocytosis. Bone 105:219–225CrossRefPubMed
7.
Zurück zum Zitat Van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ (2012) High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 67(3):431–438CrossRefPubMed Van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ (2012) High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 67(3):431–438CrossRefPubMed
8.
Zurück zum Zitat Delling G, Ritzel H, Werner M (2001) Histological characteristic and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases. Pathologe 22:132–140CrossRefPubMed Delling G, Ritzel H, Werner M (2001) Histological characteristic and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases. Pathologe 22:132–140CrossRefPubMed
9.
Zurück zum Zitat Van der Veer E, Arends S, Van der Hoek S et al (2014) Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis. J Allergy Clin Immunol 134(6):1413–1421CrossRefPubMed Van der Veer E, Arends S, Van der Hoek S et al (2014) Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis. J Allergy Clin Immunol 134(6):1413–1421CrossRefPubMed
11.
Zurück zum Zitat Schwartz LB (1987) Mediators of human mast cells and human mast cell subsets. Ann Allergy 58:226–235PubMed Schwartz LB (1987) Mediators of human mast cells and human mast cell subsets. Ann Allergy 58:226–235PubMed
12.
Zurück zum Zitat Macpherson JL, Kemp A, Rogers M et al (1989) Occurrence of plateletactivating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis. Clin Exp Immunol 77:391–396PubMedPubMedCentral Macpherson JL, Kemp A, Rogers M et al (1989) Occurrence of plateletactivating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis. Clin Exp Immunol 77:391–396PubMedPubMedCentral
13.
Zurück zum Zitat Theoharides TC, Boucher W, Spear K (2002) Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 128:344–350CrossRefPubMed Theoharides TC, Boucher W, Spear K (2002) Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 128:344–350CrossRefPubMed
14.
Zurück zum Zitat Brockow K, Akin C, Huber M, Metcalfe DD (2005) IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 115:216–223CrossRefPubMed Brockow K, Akin C, Huber M, Metcalfe DD (2005) IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 115:216–223CrossRefPubMed
15.
Zurück zum Zitat Chiappetta N, Gruber B (2006) The role of mast cells in osteoporosis. Semin Arthritis Rheum 36:32–36CrossRefPubMed Chiappetta N, Gruber B (2006) The role of mast cells in osteoporosis. Semin Arthritis Rheum 36:32–36CrossRefPubMed
16.
Zurück zum Zitat Seitz S, Barvencik F, Koehne T, Priemel M, Pogoda P, Semler J, Minne H, Pfeiffer M, Zustin J, Püschel K, Eulenburg C, Schinke T, Amling M (2013) Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporos Int 24:2325–2334CrossRefPubMed Seitz S, Barvencik F, Koehne T, Priemel M, Pogoda P, Semler J, Minne H, Pfeiffer M, Zustin J, Püschel K, Eulenburg C, Schinke T, Amling M (2013) Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporos Int 24:2325–2334CrossRefPubMed
17.
Zurück zum Zitat Rossini M, Zanotti R, Viapiana O et al (2014) Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med 127(1127):e1121–e1124 Rossini M, Zanotti R, Viapiana O et al (2014) Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med 127(1127):e1121–e1124
18.
Zurück zum Zitat Zhu JJ, Mahendran D, Lee MH, Seah J, Fourlanos S, Varadarajan S, Ghasem-Zadeh A, MacIsaac RJ, Seeman E (2018) Systemic mastocytosis identified in two women developing fragility fractures during lactation. Osteoporos Int 29(7):1671–1674CrossRefPubMed Zhu JJ, Mahendran D, Lee MH, Seah J, Fourlanos S, Varadarajan S, Ghasem-Zadeh A, MacIsaac RJ, Seeman E (2018) Systemic mastocytosis identified in two women developing fragility fractures during lactation. Osteoporos Int 29(7):1671–1674CrossRefPubMed
19.
Zurück zum Zitat Rossini M, Zanotti R, Orsolini G, Tripi G, Viapiana O, Idolazzi L, Zamò A, Bonadonna P, Kunnathully V, Adami S, Gatti D (2016) Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos Int 27:2411–2421CrossRefPubMed Rossini M, Zanotti R, Orsolini G, Tripi G, Viapiana O, Idolazzi L, Zamò A, Bonadonna P, Kunnathully V, Adami S, Gatti D (2016) Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos Int 27:2411–2421CrossRefPubMed
Metadaten
Titel
Multiple vertebral fractures as the first manifestation of systemic mastocytosis
verfasst von
Á. Acosta-Mérida
S. Ojeda-Bruno
Publikationsdatum
15.02.2019
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 5/2019
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-019-04897-9

Weitere Artikel der Ausgabe 5/2019

Osteoporosis International 5/2019 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.